Wuxi Further Pharmaceutical Co., Ltd.
Successfully passed the national intellectual property system certification
Recently, Further Pharmaceutical has made progress in the management of intellectual property rights related to the research and development of biomedicine (chemical drugs) and technical consulting services, and has passed the national intellectual property management system certification. It marks the improvement of Further Pharmaceutical's intellectual property management system and injects new impetus and management norms into the development of innovative technologies for medicines and devices.
Intellectual property compliance management system certification
Certificate number: 84025IP20571R0S.
This is proven Wuxi Further Pharmaceutical Co., Ltd. Unified social credit code: 91320206MA1MPWPT96.
Registered address: C50302, C50306, C50308, C50310, No. 1699 Huishan Avenue, Huishan Economic Development Zone, Wuxi Business address: C50302, C50310, C50315, No. 1699 Huishan Avenue, Wuxi Huishan Economic Development Zone.
The IP compliance management system meets the standards: GB/T29490-2023.
Scope of certification: Intellectual property management related to R&D and technical consulting services for biopharmaceuticals (chemicals).
Initial issuance date: 2025-07-31
Valid until: 2028-07-30.
Further Pharmaceutical is characterized by independence and vitality. It focuses on R & D, production and sales of chemical and biotechnology new drugs and generic drugs with independent R & D intellectual property rights. The company's research center has advanced generic drug and consistency evaluation technology development platform, drug synthesis technology platform, impurity orientation preparation technology platform, drug preparation research platform, analytical technology platform, pharmacology clinical technology platform. We have a professional scientific research team. The technicians are all with a bachelor's degree or above in pharmaceutical and chemical engineering. At the same time, we have hired a number of well-known experts at home and abroad as technical consultants. The scientific research results are remarkable.
Further Pharmaceutical adheres to customer-centricity and the common struggle and development of employees as the foundation. It continuously improves the company's management structure, organizational process and performance appraisal, so as to continuously improve the company's competitiveness and maintain high-speed and sustainable development. Our goal is to use our independent intellectual property technology platform for drug research and development to replace expensive imported drugs, reduce the cost of patient medication, and reduce the burden on national medical insurance. At the same time, we have achieved a virtuous circle of "driving production with new drug research and development, promoting the transformation of scientific research results through production, and further driving scientific research development".
Further Pharmaceutical Health Products Raw Materials Recommendation: PEA - Hexadecamide Ethanol CAS: 544-31-0
Product Name: Hexadecamide Ethanol
English name: Palmitoylethanolamide
CAS number: 544-31-0
Molecular formula: C18H37NO2
Molecular weight: 299.49
Purity :98%
Appearance: white or off-white powder
Standard: enterprise standard
Chinese alias category anti-inflammatory and analgesic :PEA
Hexadecamide ethanol (PEA) is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists. PEA has been shown to bind to nuclear receptors (nuclear receptors) and exert a great variety of biological functions associated with chronic pain and inflammation. The primary target is thought to be peroxisome proliferator-activated receptor alpha (PPAR-α). Primary Functions: Has anti-inflammatory, anti-inductive, neuroprotective, and anticonvulsant properties.
Wu Xi Further Pharmaceutical Co.,Ltd
Main Products
Palmitoylethanolamide(PEA) Micro (CAS 544-31-0)
Spermidine trihydrochloride(CAS 334-50-9)
Pterostilbene(CAS 537-42-8)
Luteolin (CAS 491-70-3)
Voglibose (CAS 83480-29-9) JP GMP
